Novavax's Updated Protein-based COVID-19 Vaccine Now an Opti

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M(TM) adjuvant,today announced that Nuvaxovid(TM) XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health

Related Keywords

Germany , India , Erika Schultz , Johnc Jacobs , Ali Chartan , Centers For Disease , Intj Environ Res Public Health , Serum Institute Of India Pvt , European Union , Council Of The European Union , World Health Organization , Drug Administration , Nasdaq , Vaccine Administration Errors , Exchange Commission , Linkedin , Novavax Inc , Emergency Use Listing , Use Listing , Chief Executive Officer , Emergency Use Authorization , Coronavirus Disease , Fact Sheet , Disease Control , Vaccine Adverse Event Reporting System , Fax Number , Telephone Number , Adverse Events , Vaccine Administration , Serum Institute , Financial Condition , Annual Report , Quarterly Reports , Protein Based Vaccines , From Classical , Ecological Footprint , Estimating Greenhouse Gas Emissions , Intj Environ Res Public , Nat Rev ,